DOW JONES NEWSWIRES

Hercules Technology Growth Capital Inc. (NASDAQ-NMS:HTGC) (HTGC) expects to book a potential gain from GlaxoSmithKline PLC's (NYSE:GSK) (GSK) agreement to acquire Sirtris Pharmaceuticals Inc. (NASDAQ-NMS:SIRT) (SIRT) for $22.50 a share, or about $720 million.

Hercules, a Palo Alto, Calif., specialty finance company, provided Sirtris, a biopharmaceutical company, with $15 million in debt financing in April 2006. Sirtris completed its initial public offering in May 2007, raising $62.4 million.

Hercules Technology didn't specify the amount of the potential gain.

-Melissa Korn; 201-938-5400; AskNewswires@dowjones.com

    (END) Dow Jones Newswires   04-24-08 1524   Copyright (c) 2008 Dow Jones & Company, Inc.